title: The use of epsilon-aminocaproic acid for the management of hemophilia in dental and oral surgery patients.
abstract: The use of epsilon-aminocaproic acid has proved to be an efficient and practical method for treating hemophiliacs who require dental work. In the past, patients requiring extractions were admitted to a hospital for approximately ten days and received replacement infusions every 12 hours during their stay. This resulted in a large expense because of the cost of the material and the hospitalization itself, not to mention the trauma sustained by the patient both physically and psychologically. Also, by decreasing the number of factor infusions, the risk of complications such as the transmission of hepatitis, allergic reaction, or inhibitor formation decreased. The same protocol using a single infusion of the appropriate factor replacement with supplementary epsilon-aminocaproic acid can be used for the management of patients with other coagulation disorders such as factor IX deficiency (Christman disease), factor XI deficiency, and von Willebrand's disease. Since this paper was submitted, seven more patients have been treated using this protocol. An additional seven odontectomies, 33 extractions, operative dentistry in 18 quadrants, and alveoloplasties in two full arches have been performed. This brings the total to  23 treatment sesions with 18 patients undergoing 124 procedures. One additional minor bleeding episode occurred, resulting in a total rate of four bleeding episodes in 23 treatment sessions and 124 procedures. Our incidence of complications secondary to epsilon-aminocaproic acid specifically remains zero.
mesh_terms: D000293:Adolescent; D000328:Adult; D000614:Aminocaproates / Q000627:therapeutic use*; D002648:Child; D003365:Costs and Cost Analysis; D005169:Factor VIII / Q000627:therapeutic use; D006467:Hemophilia A; D006801:Humans; D008297:Male; D009055:Mouth / Q000601:surgery*; D014070:Tooth / Q000601:surgery*; D014081:Tooth Extraction
chemical_list: D000614:Aminocaproates; D005169:Factor VIII